Title
Category
Credits
Event date
Cost
- Advanced Practice Provider
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Patients undergoing treatment for cancer utilize many medications that have relevant drug-gene interactions. The use of pharmacogenomic testing can assist with drug selection, drug dosing, and the development of personalized medication monitoring plans. Amber Cipriani, PharmD, BCOP, will describe some common examples of drug-gene interactions relevant to oncology. She will also discuss current efforts to expand the use of pharmacogenomic testing into current clinical practice.
- Advanced Practice Provider
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Tailored for medical providers, this session led by a physical therapist addresses challenges like speech and swallowing difficulties or pelvic floor issues in gynecological cancer. Explore the pivotal role of physical therapy in survivorship care plans and delve into current research supporting interventions for head and neck, gynecological, breast cancer, and other oncological conditions. Emphasizing interdisciplinary collaboration, we'll discuss the synergy between medical providers and physical therapists in delivering optimal cancer care. Additionally, learn the art of patient education in oncology rehabilitation, empowering medical providers to effectively communicate the role of physical therapy in cancer care.
- Patient Centered Care
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Joe Polich, MSW, LCSWA, JD will provide a foundational knowledge to providers who come in contact with patients with cancer who are also experiencing IPV. Beginning with a quick introduction to some basic concepts of the dynamics of IPV in general, we will discuss the intersection of the provision of care to a patient with cancer and the dynamics involved in IPV.
- Research to Practice
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.00 ASRT
- 1.00 ODS
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
The management of multiple myeloma is dynamic with a constantly changing landscape. Samuel M. Rubinstein, MD, MSCI, will cover recently published manuscripts and conference presentations that present practice changing data in the management of multiple myeloma.
- Research to Practice
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.50 ASRT
- 1.00 ODS
- 1.25 NCPD/CNE
- 1.00 Participation
$0.00
Matthew I. Milowsky, MD, FASCO, presents on "Update in Bladder Cancer"
- Research to Practice
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.50 ASRT
- 1.00 ODS
- 1.25 NCPD/CNE
- 1.00 Participation
$0.00
Kevin Chen, PharmD, MS, BCOP, CPP, presents on "Antibody-Drug Conjugates in Oncology: From Bench to Bedside."
- Research to Practice
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.50 ASRT
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Join Maggie M. Hodges, MD, MPH, for a surgeon's perspective on the role of cancer risk reduction through bariatric surgery, while also exploring the optimal timing of bariatric surgery in patients with a personal history of cancer.
- Patient Centered Care
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.50 ASRT
- 1.00 ODS
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Lori Ramkissoon, PhD will review advancements in molecular oncology and demonstrate how this integration of this testing has advanced treatment strategies and improved patient outcomes for diverse cancer types.
- Patient Centered Care
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.00 ODS
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Jacob Stein, MD, MPH, reviews several of the most common medical emergencies that arise when caring for patients with cancer. We highlight key aspects of presentation, diagnosis and management, with pearls for clinicians along the way.
- Advanced Practice Provider
- 1.00 NCPD/CNE
- 1.00 Participation
$0.00
Immunotherapy has made tremendous progress as cancer-directed therapy has evolved, particularly in the field of T cell-engaging therapies. Common and serious side effects of these types of therapies include Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Join us as Bejal Kikani, MSN, FNP-BC, WHNP-BC, discusses the recognition, grading, and treatment of these toxicities.